All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
EHA 2018 | Impact on outcomes of patients with DLBCL with concurrent FL or other low-grade lymphoma
On Sunday 17th June an oral abstract session took place at the 23rd Congress of the European Hematology Association (EHA). Abstract S1547 was presented by Yucai Wang, Mayo Clinic, Rochester, US, on the impact of concurrent follicular lymphoma (FL) or other low-grade lymphoma on the clinical outcomes of diffuse large B-cell lymphoma (DLBCL). The study aimed to compare clinical characteristics and outcomes of patients with concurrent lymphoma or de novo DLBCL.
Study Overview
- The study included patients with newly diagnosed DLBCL at the Mayo Clinic or University of Iowa from March 2002 to April 2015
- N = 1521 patients in the study had a diagnosis of:
- de novo DLBCL (n = 1262, 87.2%)
- DLBCL with concurrent FL (DLBCL+FL), (n = 113, 7.8%)
- DLBCL with concurrent other low-grade B-cell lymphoma (DLBCL+LG), (n = 73, 5%)
- Of the 113 patients with DLBCL+FL, 23% had discordant pathology
- Of the 73 patients with DLBCL+LG, the histology included; marginal zone lymphoma (24.7%), chronic lymphocytic leukemia (19.2%), lymphoplasmacytic lymphoma (5.5%) and unspecified (50.7%)
Key Findings
- Median event-free survival (EFS):
- DLBCL+FL vs DLBCL = 145.9 vs 101.9 months, P = 0.049
- DLBCL+LG vs DLBCL = 63.0 vs 101.9 months, P = 0.269
- 24-month EFS:
- DLBCL+FL vs DLBCL = 74.5% vs 63.9%
- DLBCL+LG vs DLBCL = 65.8% vs 63.9%
- Median overall survival (OS)
- DLBCL+FL vs DLBCL = not reached vs 139.7 months, P = 0.004
- DLBCL+LG vs DLBCL = 120.7 vs 139.7 months, P = 0.624
Dr Wang concluded that patients with DLBCL+FL at diagnosis mainly had Germinal center B-cell like (GCB) subtype, lower IPI scores and improved EFS and OS compared with de novo DLBCL patients. He added that DLBCL+FL is likely to behave similar to GCB DLBCL and that this should be taken into consideration when including these patients in DLBCL clinical trials.
References